A Mutation in the Herpes Simplex Virus Type 1 (HSV-1) UL29 Gene is Associated with Anti-Herpesvirus Drugs’ Susceptibility
Viruses · 2024
DOI: 10.3390/v16121813 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Souichi Yamada und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Virology 1, National Institute of Infectious Diseases, Tokyo 162-8640, Japan. Hauptthemen laut MEDLINE: DNA-Binding Proteins, Viral Proteins, Drug Resistance, Viral, Herpesvirus 1, Human. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Culture, Sports, Science, and Technology of Japan, Ministry of Health, Labor and Welfare Science Research Grant.
Abstract (Originalsprache)
Herpes simplex virus type 1 (HSV-1) acyclovir (ACV) resistance is acquired by mutations in the viral thymidine kinase (TK) or DNA polymerase (DNApol) genes. We previously obtained an ACV-resistant clone (HSV-1_VZV_TK_clone α) by sequential passages of HSV-1_VZV-TK, a recombinant virus which lacked its endogenous TK activity and instead expressed the varicella-zoster virus (VZV) TK ectopically. HSV-1_VZV_TK_clone α had been generated using an HSV-1_BAC in the presence of increasing concentrations of ACV. The ACV-resistant clone bore normal TK and DNApol genes. Here, we deployed next-generation full-genome sequencing of HSV-1_VZV_TK_clone α and identified a single nucleotide substitution, resulting in a P597L missense mutation in the UL29 gene product, the ICP8 protein. Recombinant HSV-1 encoding a P597L ICP8 protein was generated, and its properties and ability to confer drug resistance were analyzed. No difference in virus growth and UL29 expression was observed between the mutant recombinant, the wild type, and a revertant mutant viral strain, and susceptibility tests of these strains to ACV and other drugs using Vero, HEL, and ARPE19 cells identified that the recombinant UL29 mutant virus was resistant only to ACV. These results indicate that ICP8 may be involved in the anti-herpesvirus drugs’ mechanism of action on HSV-1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Virology 1, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
- The Faculty of Veterinary Medicine, Okayama University of Science, Imabari 794-8555, Ehime, Japan.
- Center for Surveillance, Immunization and Epidemiologic Research, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
- Health and Welfare Bureau, Sapporo City 060-8611, Hokkaido, Japan.
ORCID-Profile: Miho Shibamura
Förderung
- Ministry of Education, Culture, Sports, Science, and Technology of Japan
- Ministry of Health, Labor and Welfare Science Research Grant
Zitieren
APA
Yamada, S., Harada, S., Fujii, H., Kinoshita, H., Nguyen, P. H. A., Shibamura, M., Yoshikawa, T., Kawahara, M., Ebihara, H., Saijo, M., & Fukushi, S. (2024). A Mutation in the Herpes Simplex Virus Type 1 (HSV-1) UL29 Gene is Associated with Anti-Herpesvirus Drugs’ Susceptibility. Viruses. https://doi.org/10.3390/v16121813
Vancouver
Yamada S, Harada S, Fujii H, Kinoshita H, Nguyen PHA, Shibamura M, et al. A Mutation in the Herpes Simplex Virus Type 1 (HSV-1) UL29 Gene is Associated with Anti-Herpesvirus Drugs’ Susceptibility. Viruses. 2024. doi:10.3390/v16121813
BibTeX
@article{Yamada2024,
author = {Yamada, Souichi and Harada, Shizuko and Fujii, Hikaru and Kinoshita, Hitomi and Nguyen, Phu Hoang Anh and Shibamura, Miho and Yoshikawa, Tomoki and Kawahara, Madoka and Ebihara, Hideki and Saijo, Masayuki and Fukushi, Shuetsu},
title = {A Mutation in the Herpes Simplex Virus Type 1 (HSV-1) UL29 Gene is Associated with Anti-Herpesvirus Drugs’ Susceptibility},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16121813}
}
EUVIMED